We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

25 hedge funds and large institutions have $5.1M invested in Bolt Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

43.91% more ownership

Funds ownership: 2.39% → 46.3% (+44%)

14% less funds holding

Funds holding: 29 → 25 (-4)

30% less capital invested

Capital invested by funds: $7.33M → $5.1M (-$2.23M)

64% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 14

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
25
Holders Change
-4
Holders Change %
-13.79%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
14
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$54.2K
2
Morgan Stanley
Morgan Stanley
New York
+$19.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$17.3K
4
NA
NewEdge Advisors
Louisiana
+$3.2K
5
Bank of America
Bank of America
North Carolina
+$7

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$157K
2
UBS Group
UBS Group
Switzerland
-$35.7K
3
BlackRock
BlackRock
New York
-$19.1K
4
State Street
State Street
Massachusetts
-$19K
5
Northern Trust
Northern Trust
Illinois
-$16.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$986K -$7 -1 -0%
TCM
2
Tang Capital Management
California
$963K -$157K -23,760 -12%
SI
3
Sofinnova Investments
California
$795K -$7 -1 -0%
PBPIA
4
Pivotal bioVenture Partners Investment Advisor
California
$546K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$341K -$7 -1 -0%
NFGH
6
Nan Fung Group Holdings
Hong Kong
$337K -$7 -1 -0%
SB
7
Samsara BioCapital
California
$303K -$13 -2 -0%
BOTOTLSJU
8
Board of Trustees of The Leland Stanford Junior University
California
$208K +$7 +1 +0%
P
9
Pfizer
New York
$181K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$108K -$1.48K -223 -1%
Renaissance Technologies
11
Renaissance Technologies
New York
$106K +$17.3K +2,618 +17%
Squarepoint
12
Squarepoint
New York
$72.2K +$54.2K +8,193 +195%
ACM
13
ADAR1 Capital Management
Texas
$62.4K -$9.43K -1,425 -12%
BlackRock
14
BlackRock
New York
$60.9K -$19.1K -2,882 -21%
Morgan Stanley
15
Morgan Stanley
New York
$20.7K +$19.8K +2,998 +516%
NA
16
NewEdge Advisors
Louisiana
$2.79K +$3.2K +483 New
TRCT
17
Tower Research Capital (TRC)
New York
$2.28K -$258 -39 -9%
Bank of America
18
Bank of America
North Carolina
$1.63K +$7 +1 +0.4%
UBS Group
19
UBS Group
Switzerland
$1.06K -$35.7K -5,392 -97%
Fidelity Investments
20
Fidelity Investments
Massachusetts
$705 -$1.88K -284 -70%
JP Morgan Chase
21
JP Morgan Chase
New York
$251 -$13 -2 -4%
SS
22
SBI Securities
Japan
$58 – – –
Barclays
23
Barclays
United Kingdom
$35 -$7 -1 -14%
SIC
24
Salem Investment Counselors
North Carolina
$12 – – –
DB
25
Danske Bank
Denmark
$6 +$7 +1 New
1
2

BOLT Hedge Fund Activity: Q2 2025 in Review

25 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2025, worth a combined $5.1M — down 30% from $7.33M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BOLT and 2 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 5 added.

The largest buyer was Squarepoint, adding an estimated $54.2K. The largest seller was Tang Capital Management, cutting an estimated $157K.

  • 25 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2025, down from 29 in Q1 2025.
  • Funds reported $5.1M of Bolt Biotherapeutics stock for Q2 2025, down 30% quarter-over-quarter.
  • 2 funds opened new Bolt Biotherapeutics positions in Q2 2025 and 6 closed out, a net change of -4 holders.
  • The largest Bolt Biotherapeutics buyer in Q2 2025 was Squarepoint, an estimated $54.2K added.
  • The largest Bolt Biotherapeutics seller in Q2 2025 was Tang Capital Management, an estimated $157K sold.

Based on aggregated 13F filings for Q2 2025.